It looks like you're using an ad blocker.

To enjoy our content, please include The Japan Times on your ad-blocker's list of approved sites.

Thank you for supporting our journalism.

  • HOME DELIVERY |
  • SUBSCRIBE |
  • Login
  • My Account
TODAY'S PRINT EDITION

The Japan Times The Japan Times

pharmaceuticals

  • Login
  • SUBSCRIBE
  • My Account
  • HOME DELIVERY ≫
  • (FREE ARTICLE)
  • MENU
  • Search
  • News
  • Opinion
  • Life
  • Community
  • Culture
  • Sports
  • City Guide
  • Support
  • Search
  • News
    • National
    • World
    • Business
    • Asia Pacific
    • Reference
    • Columns
    • Multimedia
  • Opinion
    • Editorials
    • Commentary
    • Cartoons
  • Life
    • Travel
    • Digital
    • Food & Drink
    • Environment
    • Style & Design
    • Language
    • Lifestyle
    • People
    • Columns
    • Multimedia
  • Community
    • Voices
    • Issues
    • Our Lives
    • Event listings
    • How-tos
    • Columns
  • Culture
    • Film
    • Music
    • Art
    • Stage
    • Events
    • Festivals
    • Books
    • TV
    • Columns
    • Multimedia
  • Sports
    • Rugby
    • Baseball
    • Soccer
    • Basketball
    • Sumo
    • Figure Skating
    • Tennis
    • More Sports
    • Columns
    • Multimedia
  • City Guide
    • Restaurants
    • Places
  • Support
    • About us
    • Faqs
How China's CanSino Biologics jumped to the front of the coronavirus vaccine race

Asia Pacific / Science & Health Jul 2, 2020

How China's CanSino Biologics jumped to the front of the coronavirus vaccine race

The firm has boosted its scientific prowess by tying up with the Canadian government’s largest research organization, maintaining links despite geopolitical rows.

Eisai to start clinical trial of experimental drug for COVID-19

National / Science & Health Jul 1, 2020

Eisai to start clinical trial of experimental drug for COVID-19

Japanese pharmaceutical firm Eisai Co. is set to start clinical trials in the United States of its experimental drug eritoran in the battle against coronavirus, with results potentially available by the year-end, the company said Wednesday. Eisai will test eritoran, initially developed to treat severe ...

Fujifilm ties up with Indian firm on potential COVID-19 drug Avigan

Business Jul 1, 2020

Fujifilm ties up with Indian firm on potential COVID-19 drug Avigan

The drug has yet to be approved by the Japanese government for coronavirus treatment, with clinical testing delayed due to insufficient enrollment.

Wanted: More COVID-19 patients in Japan ... for clinical trials

National / Science & Health Jun 24, 2020

Wanted: More COVID-19 patients in Japan ... for clinical trials

by Rocky Swift

Japan has become a victim of its own success as slowing new infections have led to a shortage of patients to enroll in trials for treatments and vaccines.

National / Science & Health Jun 23, 2020

Osaka's Rohto to begin stem cell clinical trial for COVID-19 in August

Rohto Pharmaceutical Co. said Tuesday it will begin a clinical trial in August using stem cells for a potential treatment for patients severely ill with COVID-19. The Osaka-based drugmaker said it will be the first time in Japan that domestic stem cells have been used ...

Gilead targets remdesivir supply for 2 million COVID-19 patients by year-end

Business / Corporate Jun 23, 2020

Gilead targets remdesivir supply for 2 million COVID-19 patients by year-end

The company also said it hoped to start trials in August of an easier-to-use inhaled version of the medicine, which is currently administered only intravenously.

Japan drugmaker to tie up with universities to develop new test method for coronavirus

Business / Corporate Jun 22, 2020

Japan drugmaker to tie up with universities to develop new test method for coronavirus

Japanese pharmaceutical company Shionogi & Co. said Monday that it will collaborate with universities in the country to put into practical use a new testing method for the novel coronavirus.

National / Science & Health Jun 11, 2020

Drugmaker eyes stem cell clinical test for coronavirus treatment

Japanese drugmaker Rohto Pharmaceutical Co. said Thursday it plans to launch a clinical trial using stem cells to develop a treatment for severe cases of COVID-19, the respiratory illness caused by the novel coronavirus. The Osaka-based company said the trial will use mesenchymal stem cells ...

Chugai stock surges 60% to rival Sony's value on hopes for virus treatment

Business / Financial Markets Jun 8, 2020

Chugai stock surges 60% to rival Sony's value on hopes for virus treatment

by Gearoid Reidy and Ayaka Maki

Chugai Pharmaceutical is now Japan's biggest drug company by market value after overtaking Daiichi Sankyo and Takeda Pharmaceutical.

Fujifilm's COVID-19 drug research will drag on into July, source says

Business Jun 7, 2020

Fujifilm's COVID-19 drug research will drag on into July, source says

The recent fall in the number of confirmed infections has made it difficult to reach the enrollment target of 96 patients.

Scientists hunt pandemic hot spots in race to test vaccines

World / Science & Health Jun 2, 2020

Scientists hunt pandemic hot spots in race to test vaccines

The first wave of the COVID-19 pandemic may be waning. For vaccine developers, that could be a problem. Scientists in Europe and the United States say the relative success of draconian lockdown and social distancing policies in some areas and countries means virus transmission rates ...

After fast-tracking Japanese COVID-19 drug, Russia to roll out 'game changer' next week

World / Science & Health Jun 1, 2020

After fast-tracking Japanese COVID-19 drug, Russia to roll out 'game changer' next week

Russia will start administering its first approved antiviral drug to treat coronavirus patients next week, its state financial backer told Reuters, a move it described as "a game changer" that should speed a return to normal economic life. Russian hospitals can begin giving the drug ...

« 1 … 32 33 34 … 42 »
  • WHAT’S TRENDING
  • EDITORS’ PICKS
  • Nadeshiko Japan downs Costa Rica to move into knockout stage

    Thumbnail image
  • AI is rewriting the rules of $200 billion games industry

    Thumbnail image
  • Indonesia rides EV rush to domestic IPO boom

    Thumbnail image
  • 'Japan's Anatolia' becomes a home away from home for Kurds and Turks

    Thumbnail image
  • From 'Young General' to 'Supreme Leader': The evolution of Kim Jong Un

    Thumbnail image

PODCAST

  • DEEP DIVE

    A tale of two Fujis: Bullet climbs, crowds and Lizzo

Return to The Japan Times top page
JT Digital Archives The Japan Times Alpha JT Bookclub The Japan Times Jobs Education in Japan
  • SUBSCRIBE
  • NEWSLETTERS
  • ePaper Edition
  • News
    • National
    • World
    • Business
    • Asia Pacific
    • Reference
    • Columns
    • Multimedia
  • Opinion
    • Editorials
    • Commentary
    • Cartoons
  • Life
    • Travel
    • Digital
    • Food & Drink
    • Environment
    • Style & Design
    • Language
    • Lifestyle
    • People
    • Columns
    • Multimedia
  • Community
    • Voices
    • Issues
    • Our Lives
    • Event listings
    • How-tos
    • Columns
  • Culture
    • Film
    • Music
    • Art
    • Stage
    • Events
    • Festivals
    • Books
    • TV
    • Columns
    • Multimedia
  • Sports
    • Rugby
    • Baseball
    • Soccer
    • Basketball
    • Sumo
    • Figure Skating
    • Tennis
    • More Sports
    • Columns
    • Multimedia
  • City Guide
    • Restaurants
    • Places
  • Support
    • About us
    • Faqs
  • About us
  • Contact us
  • Work with us
  • Privacy Policy
  • Link policy
  • Republishing
  • FAQs
  • Announcements
  • Press
  • Sitemap
  • Advertise

The Japan Times LTD. All rights reserved.

The Japan Times